http://purl.org/np/RABL2-nqd6... RABL2-nqd6

links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance

http://www.w3.org/ns/prov#wasAttributedTo wasAttributedTo

https://orcid.org/0000-0002-3668-2627 Elif Ozkan

Elif Ozkan

2022-10-10T14:42:25.946Z

http://purl.org/np/RABL2-nqd6... RABL2-nqd6

links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance

http://www.w3.org/ns/prov#generatedAtTime generatedAtTime

2022-10-10T14:42:25.946268

Elif Ozkan

2022-10-10T14:42:25.946Z

http://purl.org/np/RABL2-nqd6... RABL2-nqd6

links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance

http://www.w3.org/ns/prov#wasQuotedFrom wasQuotedFrom

Mitoxantrone in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer. In combination with other approved drug(s) is indicated in the initial therapy of acute nonlymphocytic leukemia (ANLL) in adults. This category includes myelogenous, promyelocytic, erythroid acute leukemias.

Elif Ozkan

2022-10-10T14:42:25.946Z